In an era when there is no specific medication available to cure malaria completely, a new vaccine has shown promising results when tested on the patients. As per the study, the new vaccine would give at least 55 percent protection from the malaria.
Sanaria, the company which develops the new vaccine contains live but weakened Plasmodium falciparum sporozoites which are the early developmental stages of the parasite that causes malaria. The experimental vaccine is given in varying doses to the humans to test the results.
As per the results, the new vaccine, known as the PfSPZ gives better protection as compare to the other vaccinations. The PfSPZ would last at least for a year, confirms principal investigator of the trial Robert Seder from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.
The PfSPZ Vaccine intravenously confers long-term, sterile protection during the studies that has not been achieved with other current vaccine approaches, Robert Seder added. For the clinical trial, the researchers enrolled 101 healthy adults aged 18 to 45 years who had never had malaria.